Takahashi, Shunji
Uemura, Motohide
Kimura, Tomokazu
Kawasaki, Yoshihide
Takamoto, Atsushi
Yamaguchi, Akito
Melhem-Bertrandt, Amal
Gartner, Elaina M.
Inoue, Takashi
Akazawa, Rio
Kadokura, Takeshi
Tanikawa, Toshiki
Funding for this research was provided by:
Astellas Pharma, Inc.
Article History
Received: 30 May 2019
Accepted: 1 August 2019
First Online: 14 August 2019
Compliance with ethical standards
:
: Motohide Uemura declares no conflict of interest. Yoshihide Kawasaki declares no conflict of interest. Toshiki Tanikawa declares no conflict of interest. Amal Melhem-Bertrandt is an employee of Astellas Pharma, Inc. Takashi Inoue is an employee of Astellas Pharma, Inc. Rio Akazawa is an employee of Astellas Pharma, Inc. Takeshi Kadokura is an employee of Astellas Pharma, Inc. Elaina M. Gartner is an employee of Seattle Genetics, Inc. Shunji Takahashi declared he has received lecture fees from Eisai, BMS, and Taiho Pharmaceutical Co., Ltd. as well as research funding from MSD, AstraZeneca, Quintiles, Taiho Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co. Ltd., Daiihi Sankyo, CMIC, Novartis, and Bayer. Atsushi Takamoto declares having received personal fees from Astellas Pharma, Inc. Tomokazu Kimura declares having received personal fees from Astellas Pharma, Inc. Akito Yamaguchi declares having received compensation for promotional material from Nippion Shinyaku and Coloplast.
: All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.